It was reported that this Osimertinib plus Trametinib enhanced induction of apoptosis in EGFR-mutant NSCLC cells but not in EGFR wild-type NSCLC cells, and was very effective in killing cell clones with primary intrinsic resistance to Osimertinib [50]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.